USE OF TNF INHIBITORS IS ASSOCIATED WITH A REDUCED RISK OF DIABETES IN RA PATIENTS

被引：0
|
作者：
Lillegraven, S. [1 ]
Greenberg, J. D. [2 ]
Reed, G. W. [3 ]
Saunders, K. [4 ]
Curtis, J. R. [5 ]
Harrold, L. [6 ]
Hochberg, M. C. [7 ]
Pappas, D. [8 ]
Kremer, J. M. [9 ,10 ]
Solomon, D. H. [11 ]
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
[2] NYU Hosp Joint Dis, New York, NY USA
[3] Corrona Inc, Worcester, MA USA
[4] Corrona Inc, Southborough, MA USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] UMass Med Sch, Worcester, MA USA
[7] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[8] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[9] Albany Med Coll, Albany, NY 12208 USA
[10] Ctr Rheumatol, Albany, NY USA
[11] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：106 / 107
页数：2
相关论文
共 50 条
  • [41] ANTINUCLEAR ANTIBODY POSITIVITY IN RA PATIENTS AND ITS IMPACT ON PERSISTENCY OF TNF INHIBITORS
    Sung, Y. -K.
    Cho, S. -K.
    Kim, D.
    Won, S.
    Choi, J. I.
    Choi, C. -B.
    Kim, T. -H.
    Jun, J. -B.
    Yoo, D. -H.
    Bae, S. -C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 629 - 629
  • [42] Pioglitazone use is associated with reduced risk of Parkinson?s disease in patients with diabetes: A systematic review and meta-analysis
    Chen, Liudan
    Tao, Yangu
    Li, Jianjun
    Kang, Mengru
    JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 106 : 154 - 158
  • [43] Genetic polymorphisms in the RAS and risk of diabetes associated with the use of ACE inhibitors: The doetinchem study
    Bozkurt, B.
    Verschuren, W. M. M.
    De Boer, A.
    Grobbee, D. E.
    Geerlings, M. I.
    Heerdink, E. R.
    Stricker, B. H. C.
    Klungel, O. H.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2006, 21 : 119 - 120
  • [44] In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo
    Pisetsky, David S.
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (07) : JC79 - JC79
  • [45] Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al
    Mercer, Louise K.
    Galloway, James B.
    Lunt, Mark
    Davies, Rebecca
    Low, Audrey A. L.
    Dixon, Will G.
    Watson, Kath D.
    Symmons, Deborah P. M.
    Hyrich, Kimme L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02)
  • [46] Risks associated with use of TNF inhibitors in children with rheumatic diseases
    Marino, Achille
    Giani, Teresa
    Cimaz, Rolando
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (02) : 189 - 198
  • [47] THE USE OF EXPANDED RISK SCORE IN RA (ERS-RA) FOR THE DEFINITION OF RISK FOR MAJOR CARDIOVASCULAR EVENTS IN PATIENTS CANDIDATES TO RECEIVE JANUS KINASES INHIBITORS
    Favalli, E. G.
    Cincinelli, G.
    Orsini, F.
    Manara, M.
    Germinario, S.
    Biggioggero, M.
    Di Taranto, R.
    Ferrito, M.
    Caporali, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 851 - 852
  • [48] ARE TNF BLOCKING AGENTS ASSOCIATED WITH CHANGES IN WORK PARTICIPATION IN PATIENTS WITH RA?
    Manders, S.
    Kievit, W.
    Braakman, A.
    Hendriks, L.
    Brus, H.
    Fransen, J.
    van de Laar, M.
    van Riel, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 635 - 635
  • [49] Risk of lymphoma in patients with RA treated with anti-TNFα agents
    Franklin, JP
    Symmons, DPM
    Silman, AJ
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) : 657 - 658
  • [50] The Risk of Hospitalized Infection Associated with New Use of Abatacept versus TNF Inhibitors in Juvenile Idiopathic Arthritis
    Beukelman, Timothy
    Xie, Fenglong
    Mannion, Melissa M.
    Chen, Lang
    Zhang, Jie
    Baddley, John
    Saag, Kenneth G.
    Curtis, Jeffrey R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 270 - 271
12345